No Data
No Data
Express News | InMode Announces Morpheus8 FDA 510(k) Clearance For Soft Tissue Contraction For Fractional Radiofrequency Microneedling
Express News | Morpheus8 Secures First and Only FDA Clearance for Soft Tissue Contraction for Fractional Radiofrequency Microneedling
Barclays Lowers Price Target on InMode to $29 From $33, Maintains Overweight Rating
InMode (INMD) has an average outperform rating and price target range of $16 to $29, according to analysts polled by Capital IQ.Price: 17.78, Change: -0.10, Percent Change: -0.53
InMode Price Target Cut to $29.00/Share From $33.00 by Barclays
InMode Price Target Cut to $29.00/Share From $33.00 by
InMode Is Maintained at Overweight by Barclays
InMode Is Maintained at Overweight by
Express News | Inmode : Barclays Cuts Target Price to $29 From $33